Over the years, resistance to cell death has been recognized as one of the most common hallmarks of cancer, troubling the development of cancer therapy. As a significant strategy to maintain the balance between cell division and cell death, programmed cell death (PCD), including apoptosis, autophagy, pyroptosis, necroptosis, cuproptosis and ferroptosis, has been reported to play critical roles in cancer cell survival, proliferation and metastasis, which regulate tumor progression and are considered to be a promising strategy for cancer treatment. Programmed cell death takes an important part in homeostasis by the clearance of aberrant cells. However, misregulation of growth signals, metabolic reprogramming, and immune microenvironment impair PCD and involve in the process of cancer cell resistance to death. Non-coding RNAs (ncRNAs), which do not code for proteins, constitute the majority of the transcriptome. With the in-depth investigation of the human transcriptome, numerous ncRNAs, including microRNAs (miRNAs), small interfering RNA (siRNA), piwi-interacting RNA (piRNA), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and so on, have been demonstrated to modulate programmed cell-death processes and get involved in tumorigenesis, cancer metastasis, and therapeutic resistance. Thus, clarifying the regulatory relationship between ncRNAs and PCD and deciphering programmed cell death-related non-coding RNAs in the progression of cancer are imperative as it would give new insights into the pathogenesis and be meaningful for the development of new targeted anticancer therapeutic strategies.
This Research Topic aims at elucidating the molecular mechanism of programmed cell death-related non-coding RNAs in cancer progression and developing novel cancer therapeutic targets based on cancer-related programmed cell death and providing new insights for conquering treatment resistance.
Potential topics include but are not limited to the following:
• Exploration and verification of the novel non-coding RNAs regulating cancer cell death including autophagy, pyroptosis, necroptosis, ferroptosis and cuproptosis.
• Determination of PCD-related non-coding RNAs biomarkers in cancer immune microenvironment based on multi-omics data.
• Investigation of the molecular mechanism of non-coding RNAs modulation in PCD and cancer.
• Novel drug discovery and combinations targeting PCD-related non-coding RNAs to overcome cancer therapeutic resistance.
• Identification of specific non-coding RNAs in specific cancers and targeting these non-coding RNAs in synergy with radiotherapy or immunotherapy to induce selective cancer cell death.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Over the years, resistance to cell death has been recognized as one of the most common hallmarks of cancer, troubling the development of cancer therapy. As a significant strategy to maintain the balance between cell division and cell death, programmed cell death (PCD), including apoptosis, autophagy, pyroptosis, necroptosis, cuproptosis and ferroptosis, has been reported to play critical roles in cancer cell survival, proliferation and metastasis, which regulate tumor progression and are considered to be a promising strategy for cancer treatment. Programmed cell death takes an important part in homeostasis by the clearance of aberrant cells. However, misregulation of growth signals, metabolic reprogramming, and immune microenvironment impair PCD and involve in the process of cancer cell resistance to death. Non-coding RNAs (ncRNAs), which do not code for proteins, constitute the majority of the transcriptome. With the in-depth investigation of the human transcriptome, numerous ncRNAs, including microRNAs (miRNAs), small interfering RNA (siRNA), piwi-interacting RNA (piRNA), long non-coding RNAs (lncRNAs), circular RNAs (circRNAs) and so on, have been demonstrated to modulate programmed cell-death processes and get involved in tumorigenesis, cancer metastasis, and therapeutic resistance. Thus, clarifying the regulatory relationship between ncRNAs and PCD and deciphering programmed cell death-related non-coding RNAs in the progression of cancer are imperative as it would give new insights into the pathogenesis and be meaningful for the development of new targeted anticancer therapeutic strategies.
This Research Topic aims at elucidating the molecular mechanism of programmed cell death-related non-coding RNAs in cancer progression and developing novel cancer therapeutic targets based on cancer-related programmed cell death and providing new insights for conquering treatment resistance.
Potential topics include but are not limited to the following:
• Exploration and verification of the novel non-coding RNAs regulating cancer cell death including autophagy, pyroptosis, necroptosis, ferroptosis and cuproptosis.
• Determination of PCD-related non-coding RNAs biomarkers in cancer immune microenvironment based on multi-omics data.
• Investigation of the molecular mechanism of non-coding RNAs modulation in PCD and cancer.
• Novel drug discovery and combinations targeting PCD-related non-coding RNAs to overcome cancer therapeutic resistance.
• Identification of specific non-coding RNAs in specific cancers and targeting these non-coding RNAs in synergy with radiotherapy or immunotherapy to induce selective cancer cell death.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.